Clinical Study
Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
Table 1
Baseline characteristics stratified by presence of vertebral fracture.
| | No vertebral fracture | | Vertebral fracture | | | n = 56 | | | | | | | n = 22 | | | | | | | | Variable | Median | Mean | SD | Range | | Median | Mean | SD | Range | P value* |
| | Duration of ADT (months) | 16.5 | 39.6 | 44.7 | 0.0–10.5 | | 10.5 | 30.3 | 43.5 | 0.0–156.0 | 0.21 | | Age (years) | 77.0 | 76.5 | 8.2 | 58.0–77.5 | | 77.5 | 78.0 | 6.7 | 63.0–88.0 | 0.53 | | Weight (kg) | 83.5 | 84.8 | 17.1 | 54.5–86.7 | | 86.7 | 87.1 | 18.0 | 54.8–119.8 | 0.46 | | Height (cm) | 172.7 | 171.7 | 6.1 | 152.4–171.4 | | 171.4 | 172.5 | 7.1 | 157.5–182.9 | 0.83 | | Height loss (cm) | 5.1 | 5.8 | 3.0 | 0.8–5.8 | | 5.8 | 6.4 | 3.6 | 1.3–14.0 | 0.58 | | BMI (kg/m2) | 28.4 | 28.5 | 4.9 | 18.2–28.6 | | 28.6 | 28.7 | 5.5 | 18.3–40.4 | 0.76 | | 25-(OH) Vitamin D (ng/mL) | 31.1 | 30.3 | 14.6 | 7.0–26.1 | | 26.1 | 27.1 | 10.9 | 8.0–57.8 | 0.42 | | Serum calcium (mg/dL) | 9.7 | 9.5 | 1.3 | 0.7–9.6 | | 9.6 | 9.5 | 0.5 | 7.9–10.6 | 0.52 | | Parathyroid hormone (pg/mL) | 44.0 | 49.5 | 28.1 | 16.7–37.3 | | 37.3 | 45.9 | 28.8 | 15.8–135.0 | 0.49 | | Alkaline phosphatase (U/L) | 80.0 | 92.4 | 80.6 | 49.0–73.0 | | 73.0 | 74.2 | 17.0 | 47.0–112.0 | 0.16 | | Prostate-specific antigen (PSA) (ng/mL) | 0.3 | 6.2 | 15.1 | 0.1–0.3 | | 0.3 | 2.8 | 6.7 | 0.1–30.7 | 0.49 | | Testosterone (ng/mL) | 0.1 | 0.6 | 1.3 | 0.1–0.2 | | 0.2 | 1.4 | 1.7 | 0.1–5.9 | 0.01 |
|
|
*
P values are from the Wilcoxon rank sum test.
|
